🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Dr. Ryan Gentzler, MD comprehensively discussing lineage transformation and acquired MET amplification in EGFR mutant NSCLC. MET targeting approaches (TKI, antibody, ADC) are feasible with multiple ongoing trials. More work needs to be done to understand and target lineage

For Canadian MET exon 14, MET amplification, or MET overexpression patients, please join us in getting a MET Crusaders-Canada going. For anyone interested in screening for the Avistone MET drug in Canada, please contact the MET Crusaders: clinicaltrialsarena.com/news/avistone-…

Dr. Oliver Gautschi at #RomeLung25 updates #MET as a TKI target. Capmatinib and tepotinib approved for METex14 mutations, though outcomes in two populations are a bit lower (ATLAS, Maria Lucia Reale). Fusions and KD mutations emerging as additional targets!

Excited about the prospect of having Teliso-V enter the standard armamentarium for MET overexpression! May the approval be imminent!

Incredible visual aid to help break down This nuanced complicated topic ! So clear and concise! Printed for clinic Thursday! 🙌🏽 Ana I. Velázquez Mañana, MD, MSc, FASCO Aakash Desai, MD, MPH, FASCO #patienteducation

Great to have new protein targeting ADCs (teliso-V for high MET in refractory NSCLC most recently), but one issue is we lack of liquid biopsy or multiplex platform for all the IHc targets we need (HER2, MET, PD-L1) and likely others upcoming. Multiplex/dig path solutions here.

The MET Crusaders are elated about this most welcome FDA accelerated approval that will benefit NSCLC patients diagnosed with high MET overexpression. We thank the patients, care partners, and investigators who participated in the Phase 2 LUMINOSITY trial. Great brand name,

☑️#ASCO25 Abstract🆙 ☑️#LCSM Poster 🔥Exploratory ctDNA analyses for the EVOKE-1 study in metastatic non-small cell lung cancer (mNSCLC) 🎙️ Enriqueta Felip 📌Poster Bd2, Abstr8522 OncoAlert ASCO meetings.asco.org/2025-asco-annu…

Antibody-Drug Conjugates (ADCs) trials steal the show at the ASCO 2025. LARVOL highlights ADC drugs in #LungCancer to be presented at ASCO 2025. Get the latest #ASCO25 updates: t.ly/7TCD6 #LARVOL #CancerResearch #Oncology #ClinicalTrials #CancerData

Are we closer to blood-based screening tests for cancer? Report Cancer Discovery leveraged plasma samples from the Atherosclerosis Risk in Communities study. Multicancer early detection (MCED) test was able to detect mutations up to 3.5y before diagnosis. aacrjournals.org/cancerdiscover…

☑️#ASCO25 Abstract🆙 ☑️#LCSM Poster 🔥Dynamic changes in target protein exp. following Tx in NSCLC: Simultaneous evaluation of MET, TROP2, HER2, B7-H4, and MDM2 in paired biopsies 🎙️ Dr. Saori Murata Hidehito HORINOUCHI 📌Poster Bd71, Abstr8591 OncoAlert ASCO meetings.asco.org/2025-asco-annu…

☑️#ASCO25 Abstract🆙 ☑️#LCSM Poster 🔥MYTX-011, a cMET-targeting #ADC in patients with previously treated, advanced NSCLC: Updated dose escalation results in the phase 1 KisMET-01 🎙️ Dr. Rebecca Heist 📌Poster Bd93, Abstr8613 OncoAlert ASCO meetings.asco.org/2025-asco-annu…

☑️#ASCO25 Abstract🆙 ☑️#LCSM Poster 🔥LUMINOSITY: Telisotuzumab vedotin in pts with c-Met protein–overexp. non-sq EGFR-wild advanced NSCLC: Efficacy outcomes by prior therapy 🎙️ Dr. Jonathan Goldman Hidehito HORINOUCHI 📌Poster Bd98, Abstr8618 OncoAlert ASCO meetings.asco.org/2025-asco-annu…

Are you a MET overexpressor from any cancer type? Join our MET Overexpressors group at the MET Crusaders, metcrusaders.org Exciting pipeline updates through one on one patient navigation, oncology nursing services, clinical trials matching, and peer-to-peer counseling.

Don’t forget to check out SWOG’s amivantamab subcutaneous trial for MET patients—here is good news: Subcutaneous Amivantamab Shows 13% Infusion Reaction Rate Compared to 66% with IV in NSCLC Treatment Study - GeneOnline News …ess-1455827-5472931.cloudwaysapps.com/subcutaneous-a…

Latest from Avistone: biospace.com/press-releases…

Congratulations to the authors from the MET Crusaders!

New U.S. FDA accelerated approval: Dato-DXd for EGFR+ NSCLC after prior EGFR therapy + platinum chemo. ▫️n=114, TROPIONLung01&05 ▫️ORR: 45% ▫️DoR: 6.5 mo ⚠️ ILD, ocular AEs, stomatitis, embryo-fetal risk OncoAlert #lcsm

Wonderful talk as always from Natasha Leighl on Teliso-V for MET overexpression. Question: Should everyone be ordering Caris since Caris profiles for MET overexpression? Anatomic pathologists and medical oncologists, please order IHC to test for MET overexpression! #DAVAlung